Key result
Bariatric surgery achieved complete diabetes remission in 52.9% of Middle Eastern patients at 5 years, with Roux-en-Y gastric bypass yielding higher remission than sleeve gastrectomy.
Why the study?
Does bariatric surgery improve weight loss and glycemic control in Middle Eastern patients with Type 2 Diabetes Mellitus?
Cohort (n=238)
No
Does bariatric surgery improve weight loss and glycemic control in Middle Eastern patients with Type 2 Diabetes Mellitus?
Answers are grounded in this paper and cite their sources.
Bariatric surgery provides sustained 5-year weight loss and high rates of diabetes remission (52.9%) in Middle Eastern patients with T2DM, with early weight loss being a strong predictor of success.
Bariatric surgery has emerged as a potent intervention for patients with obesity and Type 2 Diabetes Mellitus (T2DM). To assess 5-year outcomes of bariatric surgery in Middle Eastern patients with T2DM and develop a predictive model for diabetes remission. Tertiary care center, United Arab Emirates. We conducted a retrospective cohort study of 238 T2DM patients (161 females, 67.6 %; mean age 46.8 ± 11.6 years) who underwent bariatric surgery from 2013 to 2019. Procedures included laparoscopic sleeve gastrectomy (LSG; n = 138, 58.0 %), Roux-en-Y gastric bypass (RYGB; n = 85, 35.7 %), and adjustable gastric banding (AGB; n = 15; 6.3 %). Clinical, biochemical and cardiometabolic parameters were followed for 5 years. Multivariate logistic regression analysis identified independent predictors of diabetes remission. Sustained total weight loss of 26.2 %, 29.2 %, and 27.2 % was achieved at 1, 3, and 5 years respectively. HbA1c decreased from 7.8 ± 1.5 % to 6.1 ± 1.0 % at 5 years (p < 0.001). By 5 years, 95.4 % of patients discontinued diabetes medications. Complete diabetes remission (HbA1c <6.0 % without medications) was achieved in 52.9 %, exceeding rates typically reported in randomized controlled trials of bariatric surgery (23–29 %) in Western populations. Multivariate analysis revealed baseline HbA1c <8 % (OR 2.84, 95 % CI 1.52–5.31, p = 0.001), diabetes duration <5 years (OR 3.21, 95 % CI 1.78–5.79, p < 0.001), and weight loss >20 % at 1 year (OR 4.15, 95 % CI 2.23–7.72, p < 0.001) as independent predictors of sustained remission (C-statistic = 0.842). Bariatric surgery provides sustained improvements in weight loss and glycemic control in Middle Eastern T2DM patients over 5 years. The identification of key predictors enables better patient selection and personalized treatment strategies. • 95.4 % of T2DM patients discontinued all diabetes medications at 5 years. • Complete remission (52.9 %) exceeded STAMPEDE trial rates (29 %). • Early weight loss >20 % strongest predictor of success (OR 4.15). • RYGB superior to LSG for metabolic outcomes (60 % vs 52 % remission). • Predictive model (C-statistic 0.842) enables personalized selection.
No takes yet. Share an insight, caveat, or question.
Agha et al. (2025) conducted a cohort in Type 2 Diabetes Mellitus (n=238). Bariatric surgery was evaluated on Complete diabetes remission (HbA1c <6.0 % without medications). Bariatric surgery achieved complete diabetes remission in 52.9% of Middle Eastern patients at 5 years, with Roux-en-Y gastric bypass yielding higher remission than sleeve gastrectomy.
Synapse has enriched 10 related papers. Consider them for comparative context: